A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples